WT1 Assay Portfolio Service

Tumor Target WT1

WT-1, encoded by Wilms' tumor gene 1 (WT1), plays an important role in cell growth, differentiation, apoptosis, organ development, and maintenance. WT1 has been considered as a vital tumor-associated antigen and is highly expressed in leukemias such as acute lymphoblastic leukemia (ALL) and acute myelocytic leukemia (AML), as well as solid tumors such as lung cancer, breast cancer, glioblastomas, and thyroid cancer. Therefore, it has been defined as a promising prognostic tumor marker that has been widely explored in several tumors.

What We Can Offer

Basic Research & Target Identification

We help identify and validate WT1 as a therapeutic target. Our precise WT1 expression analysis helps researchers understand its oncogenic role in cancers like leukemias and solid tumors. By quantifying WT1 levels and characterizing isoforms, we help you pinpoint its suitability for intervention and identify patient populations that may benefit from WT1-targeted approaches.

Discovery - Lead Generation & Characterization

In the discovery phase, our services evaluate potential drug candidates. We provide accurate, high-throughput WT1 assays to screen compounds for their impact on WT1 expression or activity. We also enable detailed characterization of promising leads to determine their specificity, potency, and mechanism of action against WT1, which is vital for advancing compounds toward preclinical development.

Preclinical Phase - In vitro & In vivo Studies

Creative Biolabs offers robust WT1 assay support for both in vitro and in vivo studies. Our assays enable the assessment of therapeutic efficacy in cell culture models and animal models, providing crucial data for progression to clinical trials. This includes monitoring WT1 levels as a pharmacodynamic marker or assessing the impact of WT1-targeted agents on tumor growth and metastasis.

Highlights

Unrivaled Expertise & Experience

Our deep knowledge of cancer biology and high-performance assays, developed for diverse samples, translates into optimized protocols and the avoidance of common pitfalls, accelerating your research timeline.

Cutting-Edge Solutions & Technology

We continuously invest in advanced instrumentation, including state-of-the-art qPCR, IHC, and NGS. Our rigorously validated, proprietary protocols are optimized to differentiate and quantify relevant WT1 isoforms.

Scientific Rigor & Data Quality

We use multi-level quality control and adhere to industry best practices, guaranteeing reliable, reproducible, and actionable data. This is critical for making confident decisions in clinical development, such as patient stratification or therapeutic monitoring.

Dedicated Partnership for Success

More than a service provider, we act as a committed scientific partner. We provide insightful interpretations and strategic advice to help you navigate complex biological questions and drive your projects forward.

Customer Reviews

Unparalleled Sensitivity
Creative Biolabs' service improved MRD detection in AML patients, with an advanced sensitivity crucial for guiding real-time treatment decisions. The precision of their assays provides confidence in clinical assessments and helps optimize therapeutic outcomes. - Dr. A. Sm**.

Reliable Prognostic Data
WT1 protein expression analysis via IHC provided clear prognostic data for our solid tumor cohort. Expert interpretation and high-resolution imaging helped accurately stratify patients, which is vital for tailoring treatment plans and predicting patient response. - Prof. S. Joh**.

Experience the Creative Biolabs advantage - Get a quote today.

FAQs

How does Creative Biolabs ensure the accuracy and specificity of its WT1 assays?

We utilize state-of-the-art platforms with the latest detection technologies, ensuring high sensitivity and reproducibility across all assays. This includes meticulous design of primers and probes for qPCR to specifically target relevant WT1 isoforms, highly optimized antibody panels for IHC, and stringent quality control for ELISA and NGS.

Can Creative Biolabs' service help with monitoring treatment response for WT1-targeted therapies?

Absolutely. Our highly sensitive quantitative PCR (qPCR) assays are particularly well-suited for MRD monitoring, a critical application in oncology, especially for hematological malignancies like leukemia. By detecting even minute quantities of WT1 mRNA in patient samples, our assays can track the presence of residual cancer cells after treatment with exceptional precision.

How does Creative Biolabs' WT1 assay portfolio service compare to in-house WT1 assay development?

In-house WT1 assay development is resource-intensive and time-consuming. Creative Biolabs offers validated, high-performance assays with rapid turnaround times, leveraging specialized expertise and infrastructure. This partnership saves significant time and cost while providing superior data quality.

Related Services

Cancer Biomarker Discovery

We provide comprehensive services utilizing advanced proteomics and genomics platforms, such as state-of-the-art mass spectrometry for protein profiling, high-throughput next-generation sequencing for genomic and transcriptomic analysis.

Learn More →

Gene Expression Profiling Services

We offer both high-throughput RNA sequencing, enabling whole transcriptome analysis, identification of novel transcripts, and isoform-specific quantification, as well as microarray services for targeted gene expression analysis and comparative genomics studies.